An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–1300. doi:10.1016/S0140-6736(17)33293-2
   PubMed Web of Science ®Google Scholar
• Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR project. J Glob Health. 2019;9(2):020421. doi:10.7189/jogh.09.020421
   PubMed Web of Science ®Google Scholar
• Rolfes MA, Flannery B, Chung JR, et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. Clin Infect Dis. 2019;69(11):1845–1853. doi:10.1093/cid/ciz075
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017;23(4):222–228. doi:10.1016/j.cmi.2017.02.009
   PubMed Web of Science ®Google Scholar
• Chen S, Zheng D, Li C, et al. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Biomed Res Int. 2015; 901817. doi:10.1155/2015/901817
   PubMed Web of Science ®Google Scholar
• Sui Z, Chen Q, Wu R, et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol. 2010;155(4):535–544. doi:10.1007/s00705-010-0621-4
   PubMed Web of Science ®Google Scholar
• Guo L, Zheng M, Ding Y, et al. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol. 2010;155(11):1765–1775. doi:10.1007/s00705-010-0756-3
   PubMed Web of Science ®Google Scholar
• Luo J, Zheng D, Zhang W, et al. Phylogenetic relationships of the glycoprotein gene of bovine ephemeral fever virus isolated from mainland China, Taiwan, Japan, Turkey, Israel and Australia. Virol J. 2012;9:286. doi:10.1186/1743-422X-9-268
   PubMed Web of Science ®Google Scholar
• Bullard BL, Weaver EA. Strategies targeting hemagglutinin as a universal influenza vaccine. Vaccines (Basel). 2021;9(3):257. doi:10.3390/vaccines9030257
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, et al. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–151. doi:10.1038/nm.3443
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999;5(10):1157–1163. doi:10.1038/13484
   PubMed Web of Science ®Google Scholar
• Liu W, Zou P, Ding J, et al. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 2005;7(2):171–177. doi:10.1016/j.micinf.2004.10.006
   PubMed Web of Science ®Google Scholar
• Lee YN, Kim MC, Lee YT, et al. Mechanisms of cross-protection by influenza virus M2-based vaccines. Immune Netw. 2015;15(5):213–221. doi:10.4110/in.2015.15.5.213
   PubMed Web of Science ®Google Scholar
• El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022–1031. doi:10.4049/jimmunol.0902147
   PubMed Web of Science ®Google Scholar
• Van den Hoecke S, Ehrhardt K, Kolpe A, et al. Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies. J Virol. 2017;91(7):e02500-16. doi:10.1128/JVI.02500-16
   PubMed Web of Science ®Google Scholar
• Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007;13(3):426–435. doi:10.3201/eid1303.061125
   PubMed Web of Science ®Google Scholar
• Fan J, Liang X, Horton MS, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004;22:2993–3003. doi:10.1016/j.vaccine.2004.02.021
   PubMed Web of Science ®Google Scholar
• Denis J, Acosta-Ramirez E, Zhao Y, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008;26:3395–3403. doi:10.1016/j.vaccine.2008.04.052
   PubMed Web of Science ®Google Scholar
• Grant E, Wu C, Chan KF, et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+T-cell responses. Immunol Cell Biol. 2013;91(2):184–194. doi:10.1038/icb.2012.78
   PubMed Web of Science ®Google Scholar
• Eickhoff CS, Terry FE, Peng L, et al. Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine. 2019;37:5371–5381. doi:10.1016/j.vaccine.2019.07.033
   PubMed Web of Science ®Google Scholar
• Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 2008;10:1024–1029. doi:10.1016/j.micinf.2008.07.002
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–838. doi:10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Qin S, Tang X, Chen Y, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7(1):166), doi:10.1038/s41392-022-01007-w
   PubMed Web of Science ®Google Scholar
• Arevalo CP, Bolton MJ, Le Sage V, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378(6622):899–904. doi:10.1126/science.abm0271
   PubMed Web of Science ®Google Scholar
• Chivukula S, Plitnik T, Tibbitts T, et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines. 2021;6(1):153. doi:10.1038/s41541-021-00420-6
   PubMed Web of Science ®Google Scholar
• Pardi N, Parkhouse K, Kirkpatrick E, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun. 2018;9(1):3361. doi:10.1038/s41467-018-05482-0
   PubMedGoogle Scholar
• Freyn AW, da Silva R, Rosado J, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28(7):1569–1584. doi:10.1016/j.ymthe.2020.04.018
   PubMed Web of Science ®Google Scholar
• Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326–3334. doi:10.1016/j.vaccine.2019.04.074
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316–1327. doi:10.1016/j.ymthe.2017.03.035
   PubMed Web of Science ®Google Scholar
• Zhuang X, Qi Y, Wang M, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel). 2020;8(1):123. doi:10.3390/vaccines8010123
   PubMed Web of Science ®Google Scholar
• Pardi N, Carreno JM, O'Dell G, et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun. 2022;13(1):4677. doi:10.1038/s41467-022-32149-8
   PubMed Web of Science ®Google Scholar
• van de Ven K, Lanfermeijer J, van Dijken H, et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci Adv. 2022;8(50):eadc9937. doi:10.1126/sciadv.adc9937
   PubMed Web of Science ®Google Scholar
• Lee YT, Ko EJ, Lee Y, et al. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS One. 2018;13(1):e0190868. doi:10.1371/journal.pone.0190868
   PubMed Web of Science ®Google Scholar
• Cros JF, Garcia-Sastre A, Palese P. An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic. 2005;6(3):205–213. doi:10.1111/j.1600-0854.2005.00263.x
   PubMed Web of Science ®Google Scholar
• Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16(12):1289–1296. doi:10.1038/s41592-019-0619-0
   PubMed Web of Science ®Google Scholar
• Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573–3587.e29. doi:10.1016/j.cell.2021.04.048
   PubMed Web of Science ®Google Scholar
• Wang P, Palese P, Neill O, et al. The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol. 1997;71(3):1850–1856. doi:10.1128/jvi.71.3.1850-1856.1997
   PubMed Web of Science ®Google Scholar
• Weber F, Kochs G, Gruber S, et al. A classical bipartite nuclear localization signal on thogoto and influenza A virus nucleoproteins. Virology. 1998;250(1):9–18. doi:10.1006/viro.1998.9329
   PubMed Web of Science ®Google Scholar
• Bullido R, Gomez-Puertas P, Albo C, et al. Several protein regions contribute to determine the nuclear and cytoplasmic localization of the influenza A virus nucleoprotein. J Gen Virol. 2000;81(Pt 1):135–142. doi:10.1099/0022-1317-81-1-135
   PubMedGoogle Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588. doi:10.1084/jem.20171450
   PubMed Web of Science ®Google Scholar
• Stemberger C, Neuenhahn M, Buchholz VR, et al. Origin of CD8 + effector and memory T cell subsets. Cell Mol Immunol. 2007;4(6):399–405.
   PubMed Web of Science ®Google Scholar
• Huster KM, Stemberger C, Busch DH. Protective immunity towards intracellular pathogens. Curr Opin Immunol. 2006;18(4):458–464. doi:10.1016/j.coi.2006.05.008
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Charles TP, Joag V, et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat Med. 2020;26(6):932–940. doi:10.1038/s41591-020-0858-8
   PubMed Web of Science ®Google Scholar
• Schenkel JM, Fraser KA, Beura LK, et al. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science. 2014;346(6205):98–101. doi:10.1126/science.1254536
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44. doi:10.1016/S1473-3099(11)70295-X
   PubMed Web of Science ®Google Scholar
• Zheng M, Luo J. Progress in research of broad-spectrum influenza vaccines based on conserved antigens of influenza virus. Int J Biologicals. 2019;42(4):198–202.
   Google Scholar
• Kavishna R, Kang TY, Vacca M, et al. A single-shot vaccine approach for the universal influenza A vaccine candidate M2e. Proc Natl Acad Sci U S A. 2022;119(13):e2025607119. doi:10.1073/pnas.2025607119
   PubMed Web of Science ®Google Scholar
• Liu JX, Zhang Y, An M, et al. Diversity of Th1/Th2 immunity in mice with acute lung injury induced by the H1N1 influenza virus and lipopolysaccharides. J Infect Dev Ctries. 2019;13(6):536–544. doi:10.3855/jidc.10338
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Morgan TM, Dutton RW. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol. 1999;163:723–727. doi:10.4049/jimmunol.163.2.723
   PubMed Web of Science ®Google Scholar
• Huber VC, McKeon RM, Brackin MN, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13(9):981–990. doi:10.1128/CVI.00156-06
   PubMed Web of Science ®Google Scholar